Abstract
In the last decade radiotracers have been gradually growing in importance as aids for the development of new drugs. This development has been most pronounced for Psychiatric and Neurologic drugs [1, 2], but has more recently been adapted to the development of drugs against cancer. In this mini-review, we describe how advances in molecular imaging of cancer are likely to lead to advances in development and improved application of anti-cancer drugs [3]. We will focus on 4 aspects of use of radiotracers: 1) for treatment response assessment; 2) for the study of kinetics and pharmacology of novel drugs, including bioavailability and local tumor concentration; 3) the identification of the biologic target at the cellular level; 4) the combination of nanocarriers and radioisotopes to improve biodistribution.
Keywords: Drug Development, radiotracers, molecular imaging, anti-cancer drugs, Cancer Biology
Current Pharmaceutical Design
Title: Cancer Drug Development with the Help of Radiopharmaceuticals: Academic Experience
Volume: 15 Issue: 9
Author(s): Steven M. Larson
Affiliation:
Keywords: Drug Development, radiotracers, molecular imaging, anti-cancer drugs, Cancer Biology
Abstract: In the last decade radiotracers have been gradually growing in importance as aids for the development of new drugs. This development has been most pronounced for Psychiatric and Neurologic drugs [1, 2], but has more recently been adapted to the development of drugs against cancer. In this mini-review, we describe how advances in molecular imaging of cancer are likely to lead to advances in development and improved application of anti-cancer drugs [3]. We will focus on 4 aspects of use of radiotracers: 1) for treatment response assessment; 2) for the study of kinetics and pharmacology of novel drugs, including bioavailability and local tumor concentration; 3) the identification of the biologic target at the cellular level; 4) the combination of nanocarriers and radioisotopes to improve biodistribution.
Export Options
About this article
Cite this article as:
Larson M. Steven, Cancer Drug Development with the Help of Radiopharmaceuticals: Academic Experience, Current Pharmaceutical Design 2009; 15 (9) . https://dx.doi.org/10.2174/138161209787581959
DOI https://dx.doi.org/10.2174/138161209787581959 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
FDG-PET/CT for Systemic Infections
Current Molecular Imaging (Discontinued) Risk Factors for Upper GI Damage in Low-Dose Aspirin Users and the Interaction Between <i>H. pylori</i> Infection and Low-Dose Aspirin Use
Current Pharmaceutical Design Oxidative Phosphorylation as a Target to Arrest Malignant Neoplasias
Current Medicinal Chemistry Population Diversity and its Relationship with Infectious and Tumor Diseases
Current Immunology Reviews (Discontinued) To Be-et, or Not to Be-et, That is the Question: The Role(s) of Nitrate and Nitrite in Health and Illness
Reviews on Recent Clinical Trials MicroRNAs in Esophageal Adenocarcinoma: Functional Significance and Potential for the Development of New Molecular Disease Markers
Current Pharmaceutical Design Apoptosis-related BCL2-family Members: Key Players in Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry A Stress Repair Mechanism That Maintains Vertebrate Structure During Stress
Cardiovascular & Hematological Disorders-Drug Targets Cellular Iron Homeostasis and Therapeutic Implications of Iron Chelators in Cancer
Current Pharmaceutical Biotechnology MicroRNAs as Tools and Effectors for Patient Treatment in Gastrointestinal Carcinogenesis
Current Drug Targets Non-IgE Mediated Food Allergy – Update of Recent Progress in Mucosal Immunity
Inflammation & Allergy - Drug Targets (Discontinued) Development of personalized molecular therapy for acute myeloid leukemia
Current Pharmaceutical Biotechnology Aberrant Activation of Arachidonic Acid and Eicosanoid Pathways-Targets for Treating Prostate Cancer
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Erdafitinib as a Novel and Advanced Treatment Strategy of Metastatic Urothelial Carcinoma
Anti-Cancer Agents in Medicinal Chemistry Metastasis: Recent Discoveries and Novel Perioperative Treatment Strategies with Particular Interest in the Hemostatic Compound Desmopressin
Current Pharmaceutical Biotechnology Novel non-invasive Adjunctive Techniques for Early Oral Cancer Diagnosis and Oral Lesions Examination
Current Pharmaceutical Design Evaluation of Anticancer, Antibacterial and Antioxidant Properties of a Medicinally Treasured Fern Tectaria coadunata with its Phytoconstituents Analysis by HR-LCMS
Anti-Cancer Agents in Medicinal Chemistry Ag+ Complexes as Potential Therapeutic Agents in Medicine and Pharmacy
Current Medicinal Chemistry Methionine Aminopeptidases as Potential Targets for Treatment of Gastrointestinal Cancers and other Tumors
Current Drug Targets Phytochemicals for Breast Cancer Therapy: Current Status and Future Implications
Current Cancer Drug Targets